Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use

References

• Turner JR, Karnad DR, Kothari S. Cardiovascular safety in drug development and therapeutic use: new methodologies and evolving regulatory landscapes. Switzerland: Springer International Publishing; 2017.
   Google Scholar
• Institute of Medicine of the National Academies. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press; 2007.
   Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808–815.
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Tan CTC, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. Jama. 1991;266:1672–1677.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart: a challenge that Cardioncology should not miss. Curr Cardiol Rep. 2016;18:51.
   PubMed Web of Science ®Google Scholar
• Ferri N, Siegl P, Corsini A, et al. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther. 2013;138:470–484.
   PubMed Web of Science ®Google Scholar
• Garattini S. Evaluation of benefit-risk. Pharmacoeconomics. 2010;28:981–986.
   PubMed Web of Science ®Google Scholar
• Turner JR, Panicker GK, Karnad DR, et al. Cardiovascular safety monitoring during oncology drug development and therapy. Am J Ther. 2014;21:512–522.
   PubMed Web of Science ®Google Scholar
• Madonna R, Cadeddu C, Deidda M, et al. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a position paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev. 2015;20:621–631.
   PubMed Web of Science ®Google Scholar
• Maillet A, Tan K, Chai X, et al. Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. Sci Rep. 2016;6:25333.
   PubMed Web of Science ®Google Scholar
• Smith AS, Macadangdang J, Leung W, et al. Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening. Biotechnol Adv. 2017;35:77–94.
   PubMed Web of Science ®Google Scholar
• Cui G, Chen H, Cui W, et al. FGF2 prevents sunitinib-induced cardiotoxicity in zebrafish and cardiomyoblast H9c2 cells. Cardiovasc Toxicol. 2016;16:46–53.
   PubMed Web of Science ®Google Scholar
• Kim DM, Kim H, Yeon JH, et al. Identification of a mitochondrial DNA polymerase affecting cardiotoxicity of sunitinib using a genome-wide screening on S. pombe deletion library. Toxicol Sci. 2016;149:4–14.
   PubMed Web of Science ®Google Scholar
• Christian JB, Finkle JK, Ky B, et al. Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. Am Heart J. 2012;164:846–855.
   PubMed Web of Science ®Google Scholar
• Pickering T, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368–2374.
   PubMed Web of Science ®Google Scholar
• Think Tank Synopsis CSRC. Use of real world data to assess cardiovascular safety. Available at http://www.cardiac-safety.org/wp-content/uploads/2016/12/Synopsis_19Oct2016-CSRC-Think-Tank-on-Use-of-Real-World-Data_FINAL_17Nov2016-1.pdf(Accessed 10th February 2017).
   Google Scholar
• Christenson ES, James T, Agrawal V, et al. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48:223–235.
   PubMed Web of Science ®Google Scholar
• Blaes AH, Rehman A, Vock DM, et al. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc Health Risk Manag. 2015;11:591–594.
   PubMedGoogle Scholar
• Lenihan DJ, Stevens PL, Massey M, et al. The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study. J Card Fail. 2016;22:433–438.
   PubMed Web of Science ®Google Scholar
• Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. Clin Oncol. 2016Nov28. Epub ahead of print.
   Google Scholar
• Pituskin E, Haykowsky M, McNeely M, et al. Rationale and design of the multidisciplinary Team IntervenTion in cArdio-oNcology study (TITAN). BMC Cancer. 2016;16:733.
   PubMed Web of Science ®Google Scholar
• Rygiel K. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: insights from recent clinical trials. Indian J Pharmacol. 2016;48:490–497.
   PubMed Web of Science ®Google Scholar
• Spallarossa P, Maurea N, Cadeddu C, et al. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1):S84–92.
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG). 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–2801.
   PubMed Web of Science ®Google Scholar
• Smith TA, Phyu SM, Akabuogu EU. Effects of administered cardioprotective drugs on treatment response of breast cancer cells. Anticancer Res. 2016;36:87–93.
   PubMed Web of Science ®Google Scholar
• Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388:2665–2712.
   PubMed Web of Science ®Google Scholar
• Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125:14–22.
   PubMed Web of Science ®Google Scholar
• Benziger CP, Roth GA, Moran AE. The global burden of disease study and the preventable burden of NCD. Glob Heart. 2016;11:393–397.
   PubMed Web of Science ®Google Scholar
• Whelton PK, He J, Appel LJ, et al. National high blood pressure education program coordinating committee. primary prevention of hypertension: clinical and public health advisory from the national high blood pressure education program. Jama. 2002;288:1882–1888.
   PubMed Web of Science ®Google Scholar
• Sager P, Heilbraun J, Turner JR, et al. Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. 2013. Am Heart J. 2013;165:477–488.
   PubMed Web of Science ®Google Scholar
• O’Brien E, Turner JR. Assessing blood pressure responses to noncardiovascular drugs: the beneficial role of ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2013;15:55–62.
   PubMed Web of Science ®Google Scholar
• Gottfridsson C, Panfilov S, Ebrahimi A, et al. Drug-induced blood pressure increase - recommendations for assessment in clinical and non-clinical studies. Expert Opin Drug Saf. 2017;16:215–225.
   PubMed Web of Science ®Google Scholar
• Authier S, Pugsley MK, Curtis MJ. Haemodynamic assessment in safety pharmacology. In: Pugsley MK, Curtis MJ, Eds.. Principles of safety pharmacology: handbook of experimental pharmacology 229. Berlin: Springer-Verlag; 2015. p. 221–241.
   Google Scholar
• Kindman LA, Turner JR, Lee J. Blood pressure measurement modalities: a primer for busy practitioners. J Clin Hypertens (Greenwich). 2016;18:262–266.
   PubMed Web of Science ®Google Scholar
• Myers MG, Campbell NR. Unfounded concerns about the use of automated office blood pressure measurement in SPRINT. J Am Soc Hypertens. 2016;10:903–905.
   PubMed Web of Science ®Google Scholar
• Stergiou GS, Kollias A, Zeniodi M, et al. Home blood pressure monitoring: primary role in hypertension management. Curr Hypertens Rep. 2014;16:462.
   PubMed Web of Science ®Google Scholar
• White WB, Gulati V. Managing hypertension with ambulatory blood pressure monitoring. Curr Cardiol Rep. 2015;17:2.
   PubMed Web of Science ®Google Scholar
• O’Brien E, Dolan E, Atkins N. Failure to provide ABPM to all hypertensive patients amounts to medical ineptitude. J Clin Hypertens (Greenwich). 2015;17:462–465.
   PubMed Web of Science ®Google Scholar
• Turner JR, Viera AJ, Shimbo D. Ambulatory blood pressure monitoring in clinical practice: a review. Am J Med. 2015;128:14–20.
   PubMed Web of Science ®Google Scholar
• Stockbridge S. Letter to the Editor: ABPM part of FDA reviews. Drug Inf J. 2011;45:567.
   Google Scholar
• Staessen JA, Li Y, Hara A, et al. Blood pressure measurement anno 2016. Am J Hypertens. 2017 Jan 4;hpw148. Epub ahead of print.
   PubMedGoogle Scholar
• O’Brien E. Letter to the Editor: reply to Dr Stockbridge. Drug Inf J. 2011;45:567–568.
   Google Scholar
• Satin L. Letter to the Editor: ABPM in clinical research trials. Drug Inf J. 2011;45:568.
   Google Scholar
• White WB, Turner JR, Sica DA, et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2013;8:743–757.
   Web of Science ®Google Scholar
• Izzo JL Jr, Tobe SW. Should age determine hypertension management? Recommendations from current guidelines. J Am Soc Hypertens. 2016;10:7–9.
   PubMed Web of Science ®Google Scholar
• Weber MA. (Professor of Medicine, State University of New York: Downstate Medical Center.) Personal communication. January 4th 2017.
   Google Scholar
• Sinn DI, Gibbons CH. Pathophysiology and treatment of orthostatic hypotension in Parkinsonian disorders. Curr Treat Options Neurol. 2016;18:28.
   PubMed Web of Science ®Google Scholar
• Kuritzky L, Espay AJ, Gelblum J, et al. Diagnosing and treating neurogenic orthostatic hypotension in primary care. Postgrad Med. 2015;127:702–715.
   PubMed Web of Science ®Google Scholar
• Matinolli M, Korpelainen JT, Korpelainen R, et al. Orthostatic hypotension, balance and falls in Parkinson’s disease. Mov Disord. 2009;24:745–751.
   PubMed Web of Science ®Google Scholar
• McDonald C, Newton JL, Burn DJ. Orthostatic hypotension and cognitive impairment in Parkinson’s disease: causation or association?. Mov Disord. 2016;31:937–946.
   PubMed Web of Science ®Google Scholar
• Robertson AD, Messner MA, Shirzadi Z, et al. Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. Parkinsonism Relat Disord. 2016;22:80–86.
   PubMed Web of Science ®Google Scholar
• Udow SJ, Robertson AD, MacIntosh BJ, et al. ‘Under pressure’: is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies?. J Neurol Neurosurg Psychiatry. 2016;87:1311–1321.
   PubMed Web of Science ®Google Scholar
• Schoenberger JA. Drug-induced orthostatic hypotension. Drug Saf. 1991;6:402–407.
   PubMed Web of Science ®Google Scholar
• Jodaitis L, Vaillant F, Snacken M, et al. Orthostatic hypotension and associated conditions in geriatric inpatients. Acta Clin Belg. 2015;70:251–258.
   PubMed Web of Science ®Google Scholar
• Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes. Acta Diabetol. 2003;40:S358–S361.
   PubMedGoogle Scholar
• Nissen SE, Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356:2457–2471. Epub 2007 May 21.
   PubMed Web of Science ®Google Scholar
• Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. Bmj. 2011;342:d1309.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry. Diabetes Mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December 2008. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf (Accessed 10th February 2017)
   Google Scholar
• EMA. Guideline on the clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. November 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf (Accessed 10th February 2017)
   Google Scholar
• Geiger MJ, Mehta C, Turner JR, et al. Clinical development approaches and statistical methodologies to prospectively assess the cardiovascular risk of new antidiabetic therapies for type 2 diabetes. Ther Innovation Regul Sci. 2015;49:50–64.
   PubMed Web of Science ®Google Scholar
• Hoogwerf BJ, Manner DH, Fu H, et al. Perspectives on some controversies in cardiovascular disease risk assessment in the pharmaceutical development of glucose-lowering medications. Diabetes Care. 2016;39(Suppl 2):S219–S227.
   Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med.. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med.. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Summary FDA Minutes of the endocrinologic and metabolic drugs advisory committee meeting, June 28th 2016. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm518911.pdf (Accessed 10th February 2017).
   Google Scholar
• Turner JR, Caveney E, Gillespie BS, et al. Letter to the Editor. With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs. Euro Heart J Cardiovasc Pharmacother. 2017 Jan 24;pvw047. [ Epub ahead of print].
   Google Scholar
• FDA News Release, December 2nd 2016. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm531517.htm (Accessed 10th February 2017).
   Google Scholar
• Pappachan JM, Viswanath AK. Medical management of diabesity: do we have realistic targets?. Curr Diab Rep. 2017;17:4.
   PubMed Web of Science ®Google Scholar
• Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017;19:43–53.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–2076.
   PubMed Web of Science ®Google Scholar
• Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164:705–714.
   PubMed Web of Science ®Google Scholar
• Ampudia-Blasco FJ, Romera I, Ariño B, et al. Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?. Int J Gen Med. 2017;10:23–26.
   PubMed Web of Science ®Google Scholar
• Standl E, Schnell O, McGuire DK, et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol. 2017Jan25. Epub ahead of print.
   PubMedGoogle Scholar
• Zannad F, Gattis Stough W, Lipicky RJ. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Euro Heart J Cardiovasc Pharmacother. 2016;2:200–205.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis. 2010;53:88–93.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Hartlage G, DeCara J, et al. Cardio-oncology training: a proposal from the international cardioncology society and canadian cardiac oncology network for a new multidisciplinary specialty. J Card Fail. 2016;22:465–471.
   PubMed Web of Science ®Google Scholar
• Brown SA, Sandhu N. Proposing and meeting the need for interdisciplinary cardio-oncology subspecialty training. J Card Fail. 2016;22:934–935.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Dent S, Carver J. Letter to the Editor. Response: proposing and meeting the need for interdisciplinary cardio-oncology subspecialty training by Sherry-Ann Brown, MD, PhD and Nicole Sandhu, MD, PhD. J Card Fail. 2016;22:936.
   PubMed Web of Science ®Google Scholar
• Fiuza M, Ribeiro L, Magalhães A, et al. Organization and implementation of a cardio-oncology program. Rev Port Cardiol. 2016;35:485–494.
   PubMedGoogle Scholar
• Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166:240–249.e1.
   PubMed Web of Science ®Google Scholar
• FDA. Drug Safety Communication. FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. 15th November 2013. Available at: http://www.fda.gov/downloads/drugs/drugsafety/ucm381108.pdf (Accessed 10th February 2017)
   Google Scholar
• FDA. Rosiglitazone-containing diabetes medicines: drug Safety Communication - FDA Eliminates the Risk Evaluation and Mitigation Strategy (REMS). 16th December 2015. Available at: http://www.fda.gov/downloads/drugs/drugsafety/ucm381108.pdf (Accessed 10th February 2017)
   Google Scholar
• Yabe D, Seino Y. Cardiovascular safety trials of incretin-based drugs: what do they mean?. J Diabetes Investig. 2016 Sep 9. Epub ahead of print.
   Google Scholar
• Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience. N Engl J Med. 2013;369:1285–1287.
   PubMed Web of Science ®Google Scholar
• De Leeuw AE, De Boer RA. Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects. Euro Heart J Cardiovasc Pharmacother. 2016;2:244–255.
   PubMed Web of Science ®Google Scholar
• Carlson CJ, Santamarina ML. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Expert Opin Drug Saf. 2016;15:1401–1412.
   PubMed Web of Science ®Google Scholar
• Avogaro A, Fadini GP, Sesti G, et al. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol. 2016;15:111.
   PubMed Web of Science ®Google Scholar
• MacIsaac RJ, Jerums G, Ekinci EI. Cardio-renal protection with empagliflozin. Ann Transl Med. 2016;4:409.
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752–772.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents: implications for future treatment strategies in type 2 diabetes mellitus. Clin Ther. 2016;38:1288–1298.
   PubMed Web of Science ®Google Scholar
• Skliros NP, Vlachopoulos C, Tousoulis D. Treatment of diabetes: crossing to the other side. Hellenic J Cardiol. 2016 Jul 25. Epub ahead of print.
   PubMedGoogle Scholar
• Anderson JE, Wright EE Jr, Shaefer CF Jr. Empagliflozin: role in treatment options for patients with type 2 diabetes mellitus. Diabetes Ther. 2017;8:33–53.
   PubMedGoogle Scholar
• Trujillo JM, Wettergreen SA, Nuffer WA, et al. Cardiovascular outcomes of new medications for type 2 diabetes. Diabetes Technol Ther. 2016;18:749–758.
   PubMed Web of Science ®Google Scholar
• Cheng JW, Badreldin HA, Patel DK, et al. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. Curr Med Res Opin. Epub ahead of print. 2017:1–26.
   PubMedGoogle Scholar
• Hamburg MA Remarks at the National Press Club Speaker Luncheon. October 6, 2010. Available at: http://www.fda.gov/NewsEvents/Speeches/ucm229195.htm (Accessed 2nd January 2017).
   Google Scholar
• Meyer RJ. The role of academic medical centers in advancing regulatory science. Clin Pharmacol Ther. 2014;95:471–473.
   PubMed Web of Science ®Google Scholar
• Grillo JA, Huang SM. Perspectives in regulatory science: translational and clinical pharmacology. Drug Discov Today Technol. 2016;21-22:67–73.
   PubMedGoogle Scholar
• Turner JR, Kowey PR, Rodriguez I, et al. Cardiac safety research consortium. The cardiac safety research consortium enters its second decade: an invitation to participate. Am Heart J. 2016;177:96–101.
   PubMed Web of Science ®Google Scholar
• Turner JR. The 50th anniversary of the Kefauver-Harris Amendments: efficacy assessment and the randomized clinical trial. J Clin Hypertens (Greenwich). 2012;14:810–815.
   PubMed Web of Science ®Google Scholar
• Turner JR, Karnad DR, Cabell CH, et al. Recent developments in the science of proarrhythmic cardiac safety of new drugs. Euro Heart J Cardiovasc Pharmacother. 2016 Dec 29. Epub ahead of print.
   PubMedGoogle Scholar
• Kardos P, Worsley S, Singh D, et al.  Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.  Int J Chron Obstruct Pulmon Dis. 2016;11:2885–2895.
   Google Scholar
• Dhanani TC, Mantovani EH, Turner JR. Clinical pharmacists’ opportunities to reduce inappropriate prescription of QT-prolonging medications: calls to action. Int J Pharm Pract. 2016 Sep 28. Epub ahead of print.
   PubMedGoogle Scholar
• Shah KS, Marwah U, Bundra K, et al. The PharmD/MD dual-degree program and its potential value in the pharmaceutical industry. Ther Innovation Regul Sci. 2016;50:839–845.
   Web of Science ®Google Scholar